candesartan cilexetil has been researched along with Cardiomegaly in 18 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to investigate changes in cardiac transforming growth factor beta 1 (TGF-beta 1), fibronectin, and collagen types I and III mRNA levels in isoprenaline induced cardiac hypertrophy, and the effects of delapril, an angiotensin converting enzyme inhibitor, and TCV-116, an angiotensin II type 1 receptor antagonist, on this hypertrophy." | 7.69 | Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. ( Iwao, H; Kim, S; Omura, T; Takeda, T; Takeuchi, K, 1994) |
| "To determine whether angiotensin II participates in the pathogenesis of cardiac hypertrophy and impairs coronary circulation in DOCA/salt hypertension, DOCA hypertensive rats were treated with candesartan cilexetil for 8 wk." | 7.69 | Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure. ( Fujita, H; Itoh, H; Kawa, T; Miki, S; Morimoto, S; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| "These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor." | 5.30 | Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. ( Ikeda, J; Miura, S; Nawata, J; Ohno, I; Shirato, K; Suzuki, J, 1999) |
| "We investigated the effects of an angiotensin II type 1 (AT1)-receptor antagonist on experimental cardiac hypertrophy, vascular thickening and nephrosclerosis, in order to determine the involvement of this receptor in the development of cardiovascular and renal damage." | 4.79 | Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype. ( Iwao, H; Kim, S, 1997) |
| " Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
| "The aim was to investigate changes in cardiac transforming growth factor beta 1 (TGF-beta 1), fibronectin, and collagen types I and III mRNA levels in isoprenaline induced cardiac hypertrophy, and the effects of delapril, an angiotensin converting enzyme inhibitor, and TCV-116, an angiotensin II type 1 receptor antagonist, on this hypertrophy." | 3.69 | Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. ( Iwao, H; Kim, S; Omura, T; Takeda, T; Takeuchi, K, 1994) |
| "Recently, it has been suggested that angiotensin II (AII) might be associated with cardiac hypertrophy and fibrosis." | 3.69 | Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. ( Dohi, K; Iwano, M; Kagoshima, T; Konishi, N; Masuda, J; Nakamura, Y; Sakaguchi, Y; Sutani, T; Tsuchihashi, M; Tsuruta, S, 1994) |
| "To determine whether angiotensin II participates in the pathogenesis of cardiac hypertrophy and impairs coronary circulation in DOCA/salt hypertension, DOCA hypertensive rats were treated with candesartan cilexetil for 8 wk." | 3.69 | Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure. ( Fujita, H; Itoh, H; Kawa, T; Miki, S; Morimoto, S; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| "Therefore, for the treatment of hypertension it is important to understand the mechanism of cardiac hypertrophy and to establish effective pharmaceutical interventions." | 2.40 | Role of the renin-angiotensin system in cardiac hypertrophy. ( Komuro, I; Yamazaki, T; Yazaki, Y, 1999) |
| "Treatment with imidapril significantly prevented the L-NAME-induced increase in the gene expression and immunoreactivity of PAI-1, but candesartan cilexetil showed no such effect." | 1.31 | Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. ( Egashira, K; Katoh, M; Mitsui, T; Narita, H; Takeshita, A, 2000) |
| "Cardiac hypertrophy was reduced by all three treatments, but to a lesser extent by hydralazine (treatment study), and this regression of cardiac hypertrophy persisted only with both types of RAS inhibition (withdrawal study)." | 1.31 | Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. ( Paull, JR; Widdop, RE, 2001) |
| "Cardiac hypertrophy was induced by constricting the abdominal aorta above the renal arteries." | 1.30 | Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy. ( Hayakawa, T; Ito, T; Matsui, H; Morishima, I; Mukawa, H; Okumura, K; Shimauchi, A; Toki, Y, 1997) |
| "These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor." | 1.30 | Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. ( Ikeda, J; Miura, S; Nawata, J; Ohno, I; Shirato, K; Suzuki, J, 1999) |
| "Furthermore, TCV-116 regressed cardiac hypertrophy and lessened the medial hypertrophy of the aorta in SHRSP." | 1.29 | Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. ( Chatani, F; Hamaguchi, A; Inada, Y; Ishimura, Y; Iwao, H; Kim, S; Miura, K; Ohta, K; Omura, T; Yukimura, T, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (72.22) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawamura, M | 1 |
| Itoh, H | 3 |
| Yura, S | 1 |
| Mogami, H | 1 |
| Fujii, T | 1 |
| Kanayama, N | 1 |
| Konishi, I | 1 |
| Jones, ES | 1 |
| Black, MJ | 1 |
| Widdop, RE | 2 |
| Mori, T | 1 |
| Nishimura, H | 1 |
| Ueyama, M | 1 |
| Kubota, J | 1 |
| Kawamura, K | 1 |
| Kim, S | 3 |
| Ohta, K | 1 |
| Hamaguchi, A | 1 |
| Omura, T | 2 |
| Yukimura, T | 1 |
| Miura, K | 1 |
| Inada, Y | 3 |
| Ishimura, Y | 2 |
| Chatani, F | 1 |
| Iwao, H | 3 |
| Takeuchi, K | 1 |
| Takeda, T | 1 |
| Kagoshima, T | 1 |
| Masuda, J | 1 |
| Sutani, T | 1 |
| Sakaguchi, Y | 1 |
| Tsuchihashi, M | 1 |
| Tsuruta, S | 1 |
| Iwano, M | 1 |
| Dohi, K | 1 |
| Nakamura, Y | 1 |
| Konishi, N | 1 |
| Takeda, K | 2 |
| Fujita, H | 2 |
| Nakamura, K | 1 |
| Uchida, A | 2 |
| Tanaka, M | 1 |
| Nakata, T | 2 |
| Sasaki, S | 2 |
| Nakagawa, M | 2 |
| Wada, T | 1 |
| Ojima, M | 1 |
| Sanada, T | 1 |
| Shibouta, Y | 1 |
| Kanagawa, R | 1 |
| Fujisawa, Y | 1 |
| Nishikawa, K | 1 |
| Mukawa, H | 1 |
| Toki, Y | 1 |
| Shimauchi, A | 1 |
| Matsui, H | 1 |
| Morishima, I | 1 |
| Okumura, K | 1 |
| Ito, T | 1 |
| Hayakawa, T | 1 |
| Obayashi, M | 1 |
| Yano, M | 1 |
| Kohno, M | 1 |
| Kobayashi, S | 1 |
| Tanigawa, T | 1 |
| Hironaka, K | 1 |
| Ryouke, T | 1 |
| Matsuzaki, M | 1 |
| Murakami, M | 1 |
| Tazawa, S | 1 |
| Nakao, K | 1 |
| Komatsu, H | 1 |
| Miki, S | 1 |
| Morimoto, S | 1 |
| Kawa, T | 1 |
| Suzuki, J | 1 |
| Ohno, I | 1 |
| Nawata, J | 1 |
| Miura, S | 1 |
| Ikeda, J | 1 |
| Shirato, K | 1 |
| Yamazaki, T | 1 |
| Komuro, I | 1 |
| Yazaki, Y | 1 |
| Katoh, M | 1 |
| Egashira, K | 1 |
| Mitsui, T | 1 |
| Takeshita, A | 1 |
| Narita, H | 1 |
| Nakaya, H | 1 |
| Sasamura, H | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
| Paull, JR | 1 |
2 reviews available for candesartan cilexetil and Cardiomegaly
| Article | Year |
|---|---|
Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1997 |
Role of the renin-angiotensin system in cardiac hypertrophy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1999 |
16 other studies available for candesartan cilexetil and Cardiomegaly
| Article | Year |
|---|---|
Angiotensin II receptor blocker candesartan cilexetil, but not hydralazine hydrochloride, protects against mouse cardiac enlargement resulting from undernutrition in utero.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Caloric Restriction; Cardiomegaly; Disease Models, Anim | 2009 |
Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Block | 2004 |
Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Benzimidazoles; Biphenyl Compounds | 1995 |
Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Nor | 1994 |
Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1994 |
Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arginine; Benzimidazoles; Biphen | 1994 |
Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Angiote | 1997 |
Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1997 |
Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 1997 |
Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventric
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardio | 1997 |
Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body | 1997 |
Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzim | 1999 |
Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts.
Topics: Actins; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 2000 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |
Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2001 |